Clinical Pharmacology Study of CS-3150 Evaluation of the effect of repeated dose of itraconazole orally administered to healthy Japanese adult male on the pharmacokinetics of CS-3150
Phase 1
Completed
- Conditions
- Healthy volunteers
- Registration Number
- JPRN-jRCT2080223231
- Lead Sponsor
- DAIICHI SANKYO Co.,Ltd.
- Brief Summary
When esaxerenone 2.5 mg was coadministered with itraconazole 200 mg, Cmax and AUC for esaxerenone increased by approximately 1.1 fold and 1.5-fold, respectively, compared to administration of esaxerenone alone. It was considered that there were no safety concerns when esaxerenone was administered concomitantly with itraconazole.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
1)Japanese male
2)Persons >= 20 years and =< 45 years of age at the time of informed consent
3)Persons with a body mass index (BMI; calculated by body weight [kg]/height [m]2) of >= 18.5 kg/m2 and < 25.0 kg/m2 at the screening examination
Exclusion Criteria
1)Persons with hypersensitivity or idiosyncratic reactions to a drug, (such as penicillin allergy)
2)Persons with drug or alcohol dependence
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method